Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Christopher A. Slapak"'
Autor:
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W. Goldman, David A. Smith, Christopher A. Slapak, Robert L. Ilaria, Ramon V. Tiu, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, Yiu-Keung Lau, Eric J. Roeland
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-12 (2017)
Abstract Background Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated i
Externí odkaz:
https://doaj.org/article/d0975f366e274a1ea6ec2e25ee746386
Autor:
Kristen N. Ganjoo, James E. Wooldridge, Brian K. Link, Mitchell R. Smith, Christopher A. Slapak, James G. Nelson, Barrett W. Allan, Susan P. Carpenter, Nam H. Dang, Damien M. Cronier, Maksim Pashkevich, Brad L. Pohlman, Sven de Vos, Andres Forero-Torres
PDF file - 69K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5bce7434c575177dc299c654e0ecb9
https://doi.org/10.1158/1078-0432.22443729.v1
https://doi.org/10.1158/1078-0432.22443729.v1
Autor:
Kristen N. Ganjoo, James E. Wooldridge, Brian K. Link, Mitchell R. Smith, Christopher A. Slapak, James G. Nelson, Barrett W. Allan, Susan P. Carpenter, Nam H. Dang, Damien M. Cronier, Maksim Pashkevich, Brad L. Pohlman, Sven de Vos, Andres Forero-Torres
PDF file - 122K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253351cf56a63c221795dc17528edcd9
https://doi.org/10.1158/1078-0432.22443726.v1
https://doi.org/10.1158/1078-0432.22443726.v1
Autor:
Kristen N. Ganjoo, James E. Wooldridge, Brian K. Link, Mitchell R. Smith, Christopher A. Slapak, James G. Nelson, Barrett W. Allan, Susan P. Carpenter, Nam H. Dang, Damien M. Cronier, Maksim Pashkevich, Brad L. Pohlman, Sven de Vos, Andres Forero-Torres
Purpose: AME-133v is a humanized monoclonal antibody engineered to have increased affinity to CD20 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) better than rituximab. Safety, pharmacokinetics, and efficacy were assessed in a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de46a6931aab8606aac50fbb6cf91bfb
https://doi.org/10.1158/1078-0432.c.6519936
https://doi.org/10.1158/1078-0432.c.6519936
Autor:
Kristen N. Ganjoo, James E. Wooldridge, Brian K. Link, Mitchell R. Smith, Christopher A. Slapak, James G. Nelson, Barrett W. Allan, Susan P. Carpenter, Nam H. Dang, Damien M. Cronier, Maksim Pashkevich, Brad L. Pohlman, Sven de Vos, Andres Forero-Torres
PDF file - 62K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2203b95dc92776076d3f6278aebb71e4
https://doi.org/10.1158/1078-0432.22443723.v1
https://doi.org/10.1158/1078-0432.22443723.v1
Autor:
Sven de Vos, Andres Forero-Torres, Ian W. Flinn, Nathan Enas, Damien M. Cronier, Mitchell R. Smith, Christopher A. Slapak, Markus Y. Mapara, James E. Wooldridge, Susan P. Carpenter, Kristen N. Ganjoo, Kenneth A. Foon, Brad Pohlman, Nam H. Dang, Brian K. Link
Publikováno v:
Leukemia & Lymphoma. 56:42-48
This phase 2 study assessed the safety and efficacy of ocaratuzumab, a humanized anti-CD20 monoclonal antibody. Fifty patients with previously treated follicular lymphoma (FL) and a low-affinity genotype of FcγRIIIa received ocaratuzumab 375 mg/m(2)
Autor:
Robert Ilaria, David Smith, Eric Roeland, Joanne Cox, Rafat Abonour, Xuejing Wang, Ramon V. Tiu, Yiu Keung Lau, Saroj Vadhan-Raj, Jay Tuttle, Jonathan W. Goldman, Sophie Callies, Christopher A. Slapak
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-12 (2017)
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-12 (2017)
Background Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron trans
Autor:
Tomohide Tamura, Hiroshi Nokihara, Karim A. Benhadji, Noboru Yamamoto, Yasuhide Yamada, Kazunori Uenaka, Christopher A. Slapak, Risa Sekiguchi, Takeshi Makiuchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1645-1655
LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and antitumor activity.Patients with advanced
Autor:
Petronella O. Witteveen, Annemarie Nol, Stijn L.W. Koolen, Marlies H.G. Langenberg, Jan H.M. Schellens, Sophie Callies, Christopher A. Slapak, Robert S. Jansen, Roelien H. Kronemeijer, Ignacio Garcia-Ribas, Jos H. Beijnen, Karim A. Benhadji, Emile E. Voest
Publikováno v:
Clinical Cancer Research, 17(18), 6071-6082. AMER ASSOC CANCER RESEARCH
Purpose: LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of daily administration of LY2334737 with or without erlotinib. Experim
Autor:
Malcolm R Ranson, Valerie Andre, Michael Burgess, Azeem Saleem, Julian C. Matthews, Sophie Callies, Patricia M Price, Anna L. Olsen, Johann S. de Bono, Joanna Davies, Peter J. McHugh, Sunil Kadam, Michael Lahn, Christopher A. Slapak, Denis C. Talbot
Publikováno v:
Clinical Cancer Research. 16:6150-6158
PURPOSE: Enhanced tumor cell survival through expression of inhibitors of apoptosis (IAP) is a hallmark of cancer. Survivin, an IAP absent from most normal tissues, is overexpressed in many malignancies and associated with a poorer prognosis. We repo